Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00897182

Enrollment

Registered

2009-05-12

Start date

2008-05-31

Completion date

2014-03-31

Last updated

2016-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

adult acute myeloid leukemia in remission, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(15;17)(q22;q12), adult acute myeloid leukemia with t(8;21)(q22;q22), childhood acute myeloid leukemia in remission, recurrent adult acute myeloid leukemia, recurrent childhood acute myeloid leukemia, secondary acute myeloid leukemia, untreated adult acute myeloid leukemia, untreated childhood acute myeloid leukemia and other myeloid malignancies

Brief summary

RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment. PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.

Detailed description

OBJECTIVES: * To identify and validate individual genes for diagnosis of three major translocations in acute myeloid leukemia. * To correlate transcript expression data in the various translocations with age, sex, race, response to treatment, and survival and with other known mutations. OUTLINE: Blood and/or bone marrow samples previously procured from patients on CALGB-9665 are obtained from the CALGB Leukemia Tissue Bank from patients enrolled on CALGB AML treatment studies. Mononuclear cells are isolated from samples and mRNA is extracted. Gene expression profiles are analyzed via custom mRNA microarray and confirmed by quantitative real-time PCR.

Interventions

GENETICmicroarray analysis

GENETICpolymerase chain reaction

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Enrolled on CALGB acute myeloid leukemia (AML) treatment studies AND concurrently enrolled on Leukemia Tissue Bank Protocol CALGB-9665 * Short-term or long-term survivor * Bone marrow and/or peripheral blood obtained at diagnosis * Leukemia is one of the following cytogenetic subtypes: * t(8;21) * t(15;17) * inv(16)

Design outcomes

Primary

Measure	Time frame
Correlation of increased or decreased expression of same transcripts with disease outcome	baseline
Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia	baseline
Identification of individual genes that are differentially expressed between the subtypes of AMLs	baseline
Correlation of the patterns of expression of the translocation-specific transcripts with age, sex, race, response to treatment, survival, and with other known mutations	baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026